Shenoy et al. (2013) reported that intraperitoneal (i.p.)injection of DIZE (15 mg/kg/day) for 2 weeks could downregulate ADAM17 mRNA levels and inhibited the loss of tissue ACE2 in myocardial cells in a chronic heart failure animal model, thus improving heart function by keeping the ACE/ACE2 ratio closer to an optimized profile. Moreover, DIZE was found to improve endothelial dysfunction and vasodilatory function in a pulmonary hypertension model (Li et al., 2018). Here, ACE2 is linked to endothelial dysfunction.